Chugai Pharmaceutical Income from Continuous Operations 2020-2025 | CHGCY

Chugai Pharmaceutical income from continuous operations for the twelve months ending March 31, 2025 was $1.699B, a 17.25% decline year-over-year.

  • Chugai Pharmaceutical annual income from continuous operations for 2024 was $2.556B, a 10.62% increase from 2023.
  • Chugai Pharmaceutical annual income from continuous operations for 2023 was $2.311B, a 19.85% decline from 2022.
  • Chugai Pharmaceutical annual income from continuous operations for 2022 was $2.883B, a 4.56% increase from 2021.

Chugai Pharmaceutical Income from Continuous Operations 2020-2025 | CHGCY

  • Chugai Pharmaceutical annual income from continuous operations for 2024 was $2.556B, a 10.62% increase from 2023.
  • Chugai Pharmaceutical annual income from continuous operations for 2023 was $2.311B, a 19.85% decline from 2022.
  • Chugai Pharmaceutical annual income from continuous operations for 2022 was $2.883B, a 4.56% increase from 2021.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$68.1B
Takeda Pharmaceutical (TAK)$46.9B
Daiichi Sankyo, - (DSNKY)$43.1B
BeOne Medicines - (ONC)$29.6B
Sandoz Group AG (SDZNY)$25B
Summit Therapeutics (SMMT)$18.1B
Merck (MKKGY)$16.5B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.2B
Stevanato Group S.p.A (STVN)$7.8B
Corcept Therapeutics (CORT)$7.6B
Madrigal Pharmaceuticals (MDGL)$6.9B
Grifols, S.A (GRFS)$6.7B
Ionis Pharmaceuticals (IONS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.3B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$3.2B
Crinetics Pharmaceuticals (CRNX)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B
Endo (NDOI)$1.6B